Biomarin Pharmaceutical (BMRN) Short-term Investments (2009 - 2025)

Biomarin Pharmaceutical has disclosed Short-term Investments across 17 years of filings, most recently posting $248.9 million for Q4 2025.

• Quarterly Short-term Investments rose 27.75% year-over-year to $248.9 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $248.9 million (up 27.75% YoY) and the FY2025 annual result came in at $248.9 million, up 27.75% from the prior year.
• Short-term Investments climbed to $248.9 million in Q4 2025, from $227.7 million in the prior quarter.
• Over five years, Short-term Investments peaked at $572.0 million in Q1 2023 and troughed at $194.9 million in Q4 2024.
• A 5-year average of $371.9 million and a median of $380.3 million in 2021 frame the typical range for Short-term Investments.
• Annual changes were most pronounced in 2022 — Short-term Investments surged 32.91% — and 2024, when it plunged 47.63%.
• Tracing BMRN's Short-term Investments over 5 years: stood at $426.6 million in 2021, then jumped by 32.91% to $567.0 million in 2022, then sank by 43.8% to $318.7 million in 2023, then sank by 38.85% to $194.9 million in 2024, then advanced by 27.75% to $248.9 million in 2025.
• Business Quant data shows BMRN's Short-term Investments at $248.9 million in Q4 2025, $227.7 million in Q3 2025, and $218.3 million in Q2 2025.